Investors Buy High Volume Call Options on Trevena (NASDAQ:TRVN)

Trevena, Inc. (NASDAQ:TRVN) was the target of unusually heavy options trading activity on Thursday. Equity investors acquired 12,105 call options on the company. This represents an increase of approximately 1,672% from the typical volume of 683 call options.

A number of research analysts have weighed in on TRVN shares. Oppenheimer reiterated a “hold” note on Trevena shares in a Friday, Oct. 1 research report. Zacks Investment Research upgraded Trevena shares from a “hold” rating to a “sell” rating in a Tuesday, Jan. 18 research note.

TRVN stock opened at $0.50 on Friday. The stock has a market capitalization of $82.75 million, a P/E ratio of -1.62 and a beta of 2.17. The company has a 50-day simple moving average of $0.63 and a 200-day simple moving average of $1.02. Trevena has a 52 week low of $0.46 and a 52 week high of $3.10.

Trevena Inc (NASDAQ:TRVN) last reported quarterly earnings data on Monday, November 15. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Trevena had a negative net margin of 7,771.74% and a negative return on equity of 53.47%. The company posted revenue of $0.18 million in the quarter, compared to $1.16 million expected by analysts. During the same quarter of the previous year, the company achieved EPS of ($0.04). On average, equity research analysts expect Trevena to post -0.33 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently changed their positions in the stock. Bank of America Corp DE increased its stake in Trevena by 48.1% during the second quarter. Bank of America Corp DE now owns 34,607 shares of the biopharmaceutical company valued at $59,000 after acquiring 11,243 additional shares last quarter. Wellington Shields Capital Management LLC purchased a new equity stake in Trevena in Q2 valued at approximately $27,000. NEXT Financial Group Inc increased its stake in shares of Trevena by 74.5% in Q3. NEXT Financial Group Inc now owns 55,429 shares of the biopharmaceutical company valued at $68,000 after purchasing an additional 23,668 shares during the period. Morgan Stanley increased its stake in Trevena shares by 5.7% in the third quarter. Morgan Stanley now owns 442,479 shares of the biopharmaceutical company valued at $544,000 after purchasing an additional 23,926 shares during the period. Finally, Amalgamated Bank purchased a new equity stake in Trevena in Q2 valued at approximately $43,000. 22.47% of the stock is held by institutional investors.

(A d)

Whether you’re looking to learn the basics of futures or you’re a seasoned veteran looking to hone your trading skills, our technical analysis guide has everything you need to succeed in today’s futures markets. today!

About Trevena

Trevena, Inc. engages in the development and commercialization of new drugs for patients with central nervous system disorders. Its product candidates include Oliceridine Injection, TRV250, TRV734 and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A.

Feature Story: Institutional Investors

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Trevena right now?

Before you consider Trevena, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Trevena didn’t make the list.

Although Trevena currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Robert D. Coleman